Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Recruiting · NCT06176989 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | Esthesioneuroblastoma, Olfactory, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, chondrosarcoma, connective tissue neoplasm, cranial nerve neuropathy, epithelial neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, olfactory nerve disorder, primitive neuroectodermal tumor, sarcoma, sinonasal undifferentiated carcinoma | Recruiting | Phase 2 | 2026-09-21 | NCT06176989 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | United States | 800 |